Yin, Ji-YeZhang, Jian-TingZhang, WeiZhou, Hong-HaoLiu, Zhao-Qian2017-12-012017-12-012018-01Yin, J.-Y., Zhang, J.-T., Zhang, W., Zhou, H.-H., & Liu, Z.-Q. (2018). eIF3a: A new anticancer drug target in the eIF family. Cancer Letters, 412(1), 81-87. https://doi.org/10.1016/j.canlet.2017.09.055https://hdl.handle.net/1805/14709eIF3a is the largest subunit of eIF3, which is a key player in all steps of translation initiation. During the past years, eIF3a is recognized as a proto-oncogene, which is an important discovery in this field. It is widely reported to be correlated with cancer occurrence, metastasis, prognosis, and therapeutic response. Recently, the mechanisms of eIF3a action in the carcinogenesis are unveiled gradually. A number of cellular, physiological, and pathological processes involving eIF3a are identified. Most importantly, it is emerging as a new potential drug target in the eIF family, and some small molecule inhibitors are being developed. Thus, we perform a critical review of recent advances in understanding eIF3a physiological and pathological functions, with specific focus on its role in cancer and anticancer drug targets.enPublisher Policyanticancerdrug targetelF3aArticle